Latest Eikon Therapeutics News & Updates

See the latest news and media coverage for Eikon. We track all announcements, press releases, and industry mentions in real time, all in one place.

Eikon Therapeutics (Eikon)

Late-stage clinical biopharmaceutical company

eikontx.com

Headquarters: Millbrae, United States
Founded year: 2019
Company type: Private company
Number of employees: 400–500
Industry: Pharmaceuticals

Last updated Today

Latest news about Eikon Therapeutics (Eikon)

In short: Eikon completed a $381 million IPO, progressed clinical trials for its EIK1001 oncology candidate, and appointed new leadership.

Company announcements

September 3 Eikon

Eikon names Ching-Pin Chang as chief scientific officer

Dr. Chang joins from Bristol Myers Squibb, bringing over two decades of expertise in drug discovery and cardiovascular research to lead the company’s scientific initiatives.

August 13 Eikon

Eikon reports Q2 2026 results and clinical updates

Seven abstracts accepted for ESMO, encouraging EIK1001 data, and $531.2 million cash.

August 11 Eikon

Eikon selects 0.60 mg/m2 dose for EIK1001 trial

The decision follows a Data Monitoring Committee recommendation in the ongoing adaptive Phase 2/3 TeLuRide-006 study in advanced melanoma.

July 27 Eikon

Eikon announces first patient dosed in TeLuRide-008 trial

The Phase 2/3 registrational study evaluates EIK1001 combined with pembrolizumab and chemotherapy as first-line therapy for stage 4 NSCLC.

Media coverage

August 21 Yahoo Finance

Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004

Eikon Therapeutics (NASDAQ:EIKN) outlined its development strategy for selective PARP1 inhibitors and its Werner helicase ...

August 14 Markets Insider

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress...

August 10 Yahoo Finance

Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...

July 27 MarketWatch

Eikon Therapeutics Shares Up on First Dose to Patient in Phase 2/3 Lung Cancer Trial

The late-stage biopharmaceutical company said the first patient has been dosed in the phase 2/3 TeLuRide-008 registrational study evaluating EIK1001 in combination with pembrolizumab and...

Never miss news about Eikon

Track Eikon and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Eikon competitors & trending companies

Browse news for competitors to Eikon and other trending companies.